Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdoid Tumor 1Osteosarcoma Recurrent 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Melanoma 1Lymphoma, Follicular 1Lung Neoplasms 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 3Bevacizumab 3Re-Irradiation 2Nivolumab 2Irinotecan 2Cetuximab 2ribociclib 1pembrolizumab 1lutetium Lu 177 dotatate 1dostarlimab 1dipinacoline glutamate 1dinutuximab 1cemiplimab 1abemaciclib 1Vorinostat 1Vincristine 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiotherapy 1Mebendazole 1Maintenance 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fluid Therapy 1Eflornithine 1Congresses as Topic 1Carboplatin 1CBLC137 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Diffuse Intrinsic Pontine Glioma × Eflornithine × Clear all
NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡